Limits...
Quantitative proteomic analysis of serum from pregnant women carrying a fetus with conotruncal heart defect using isobaric tags for relative and absolute quantitation (iTRAQ) labeling.

Zhang Y, Kang Y, Zhou Q, Zhou J, Wang H, Jin H, Liu X, Ma D, Li X - PLoS ONE (2014)

Bottom Line: A total of 105 unique proteins present in the three groups were identified, and relative expression data were obtained for 92 of them with high confidence by employing the iTRAQ-based experiments.The downregulation of gelsolin in maternal serum of fetus with CTD was further verified by Western blot.The identification of differentially expressed protein gelsolin in the serum of the pregnant women carrying a CTD fetus by using proteomic technology may be able to serve as a foundation to further explore the biomarker for detection of CTD fetus from the maternal serum.

View Article: PubMed Central - PubMed

Affiliation: Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

ABSTRACT

Objective: To identify differentially expressed proteins from serum of pregnant women carrying a conotruncal heart defects (CTD) fetus, using proteomic analysis.

Methods: The study was conducted using a nested case-control design. The 5473 maternal serum samples were collected at 14-18 weeks of gestation. The serum from 9 pregnant women carrying a CTD fetus, 10 with another CHD (ACHD) fetus, and 11 with a normal fetus were selected from the above samples, and analyzed by using isobaric tags for relative and absolute quantitation (iTRAQ) coupled with two-dimensional liquid chromatography-tandem mass spectrometry(2D LC-MS/MS). The differentially expressed proteins identified by iTRAQ were further validated with Western blot.

Results: A total of 105 unique proteins present in the three groups were identified, and relative expression data were obtained for 92 of them with high confidence by employing the iTRAQ-based experiments. The downregulation of gelsolin in maternal serum of fetus with CTD was further verified by Western blot.

Conclusions: The identification of differentially expressed protein gelsolin in the serum of the pregnant women carrying a CTD fetus by using proteomic technology may be able to serve as a foundation to further explore the biomarker for detection of CTD fetus from the maternal serum.

No MeSH data available.


Related in: MedlinePlus

Flow diagram describing the selection of the analytical data set used for iTRAQ analysis.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4230941&req=5

pone-0111645-g001: Flow diagram describing the selection of the analytical data set used for iTRAQ analysis.

Mentions: Figure 1 displays the division of the analytical data set. 12 fetuses were diagnosed with isolated CTD, 15 fetuses with isolated ACHD and 7 with multi-malformation by ultrasound examination at 20-24 weeks of gestation. Termination of pregnancy was chosen in 7 of CTD cases after diagnosis, and CTD was verified as an isolated defect by autopsy. Other CTDs, ACHDs and normal controls were confirmed by prenatal and postnatal echocardiography. 3 cases of fetal 21-trisomy, 7 cases of fetal multi-malformation, 19 cases of fetal CHD which was diagnosed at birth, and 1 case combined with pregnancy–induced hypertension and fetal malformation were excluded. After exclusion of these women and those whose serum samples were lost, 9 participants with CTD fetus, 10 participants with ACHD fetus, 11 participants with normal fetus were recruited. Table 2 shows the types of prenatally diagnosed CTDs and ACHDs from the collected samples.


Quantitative proteomic analysis of serum from pregnant women carrying a fetus with conotruncal heart defect using isobaric tags for relative and absolute quantitation (iTRAQ) labeling.

Zhang Y, Kang Y, Zhou Q, Zhou J, Wang H, Jin H, Liu X, Ma D, Li X - PLoS ONE (2014)

Flow diagram describing the selection of the analytical data set used for iTRAQ analysis.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4230941&req=5

pone-0111645-g001: Flow diagram describing the selection of the analytical data set used for iTRAQ analysis.
Mentions: Figure 1 displays the division of the analytical data set. 12 fetuses were diagnosed with isolated CTD, 15 fetuses with isolated ACHD and 7 with multi-malformation by ultrasound examination at 20-24 weeks of gestation. Termination of pregnancy was chosen in 7 of CTD cases after diagnosis, and CTD was verified as an isolated defect by autopsy. Other CTDs, ACHDs and normal controls were confirmed by prenatal and postnatal echocardiography. 3 cases of fetal 21-trisomy, 7 cases of fetal multi-malformation, 19 cases of fetal CHD which was diagnosed at birth, and 1 case combined with pregnancy–induced hypertension and fetal malformation were excluded. After exclusion of these women and those whose serum samples were lost, 9 participants with CTD fetus, 10 participants with ACHD fetus, 11 participants with normal fetus were recruited. Table 2 shows the types of prenatally diagnosed CTDs and ACHDs from the collected samples.

Bottom Line: A total of 105 unique proteins present in the three groups were identified, and relative expression data were obtained for 92 of them with high confidence by employing the iTRAQ-based experiments.The downregulation of gelsolin in maternal serum of fetus with CTD was further verified by Western blot.The identification of differentially expressed protein gelsolin in the serum of the pregnant women carrying a CTD fetus by using proteomic technology may be able to serve as a foundation to further explore the biomarker for detection of CTD fetus from the maternal serum.

View Article: PubMed Central - PubMed

Affiliation: Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

ABSTRACT

Objective: To identify differentially expressed proteins from serum of pregnant women carrying a conotruncal heart defects (CTD) fetus, using proteomic analysis.

Methods: The study was conducted using a nested case-control design. The 5473 maternal serum samples were collected at 14-18 weeks of gestation. The serum from 9 pregnant women carrying a CTD fetus, 10 with another CHD (ACHD) fetus, and 11 with a normal fetus were selected from the above samples, and analyzed by using isobaric tags for relative and absolute quantitation (iTRAQ) coupled with two-dimensional liquid chromatography-tandem mass spectrometry(2D LC-MS/MS). The differentially expressed proteins identified by iTRAQ were further validated with Western blot.

Results: A total of 105 unique proteins present in the three groups were identified, and relative expression data were obtained for 92 of them with high confidence by employing the iTRAQ-based experiments. The downregulation of gelsolin in maternal serum of fetus with CTD was further verified by Western blot.

Conclusions: The identification of differentially expressed protein gelsolin in the serum of the pregnant women carrying a CTD fetus by using proteomic technology may be able to serve as a foundation to further explore the biomarker for detection of CTD fetus from the maternal serum.

No MeSH data available.


Related in: MedlinePlus